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Abstract 
The most common cause of deaths due to cancers nowadays is lung cancer. The objective of this 
study was to prepare erlotinib loaded chitosan nanoparticles for their anticancer potential. To 
study the effect of formulation variables on prepared nanoparticles using central composite 
design. Erlotinib loaded chitosan nanoparticles were prepared by ionic gelation method using 
probe sonication technique. It was found that batch NP-7 has a maximum loading capacity and 
entrapment efficiency with a particle size (138.5 nm) which is ideal for targeting solid tumors. 
Analysis of variance was applied to the particle size, entrapment efficiency and percent 
cumulative drug release to study the fitting and the significance of the model. The batch NP-7 
showed 91.57 percent and 39.78 percent drug release after 24 h in 0.1N hydrochloric acid and 
Phosphate Buffer (PB) pH 6.8, respectively. The IC50 value of NP-7 evaluated on A549 Lung 
cancer cells was found to be 6.36 µM. The XRD of NP-7 displayed the existence of erlotinib in 
the amorphous pattern. The optimized batch released erlotinib slowly in comparison to the 
marketed tablet formulation. Erlotinib loaded chitosan nanoparticles were prepared successfully 
using sonication technique with suitable particle size, entrapment efficiency and drug release. 
The formulated nanoparticles can be utilized for the treatment of lung cancer. 
Keywords: Erlotinib, ionic gelation, probe sonication. 
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1. Introduction 
Cancer is the second largest cause of death worldwide following cardiovascular diseases and the 
most common cause of deaths due to cancers includes lung cancer, both in women and men [1]. 
Among lung cancers, non-small cell lung cancer (NSCLC) is the most common form, with the 
major population of patients having advanced stage of the disease at the time of diagnosis [2].
 
According to the World Health Organization (WHO), cancer was found responsible for around 
8.8 million deaths worldwide in 2015 among which, about 1.69 million deaths were associated 
with lung cancer only [3]. The number is expected to be increased around 19.3 million 
discovered cancer victims per annum by 2025. As per the World Cancer report of World Health 
Organization for the year 2017, approximately 9.6 million deaths were reported to be caused by 
cancer worldwide by the year 2018, and it is expected to reach the number of 22 million by the 
year 2035 [4]. 
Cancer nanotechnology is the most intriguing research area cutting across biology, chemistry, 
engineering, and medicine, aiming to develop advanced cancer therapies [4,5]. Nanotechnology 
has come as a new paradigm in the effective delivery of anticancer drugs. Advances in the design 
of nanoparticles (NPs) as drug delivery systems have provided huge opportunities in cancer 
targeted drug delivery and shown great promise in improving the therapeutic outcome of the 
already existing cancer therapies [6,7]. Owing to their small size, NPs have been endowed with 
unique characteristics; e.g., high surface area, easy surface modification, encapsulation of wide 
range of therapeutics, tunable properties, ligand conjugation and targeting capabilities [8,9]. 
Depending on the method of preparation, polymeric nanoparticles can be formulated in the size 
range of 10–1000 nm. Polymeric systems have been used in cancer therapy since 1976, when a 
controlled release system was developed by Langer and Folkman for the delivery of 
macromolecules [10]. The drug may be either adsorbed on the surface of the nanoparticles or 
encapsulated into the polymer matrix. The latter is preferred as it protects the drug from the 
surrounding environment and provides controlled release capabilities; while adsorption is used 
for attaching the targeting ligands to the surface of the nanoparticles [11].
 
After screening a number of anticancer drugs, erlotinib was selected for the present study. 
Erlotinib got approval from USFDA under the trade name TARCEVA (Genetech, OSI 
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Pharmaceuticals) for the treatment of two types of cancer including NSCLC and pancreatic 
cancer. Erlotinib falls in the novel class “targeted therapies”, which is designed to inhibit the 
epidermal growth factor receptor (EGFR) [12]. These receptors generally do not occur in normal 
cells but found very commonly on the surfaces of a number of human tumor cells and constitute 
a group of four receptors i.e., ErbB-1 (EGFR), ErbB-2 (HER2/neu), ErbB-3 (HER3) and ErbB-4 
(HER4) responsible for the continued existence of the cell [13]. When a ligand binds to EGFR, it 
leads to the phosphorylation of internal tyrosine kinase (TK) domain of the receptor and resulting 
into its activation, which further stimulates the several internal signaling pathways and thus 
affects proliferation, differentiation and cell survival. Evidence have suggested the role of this 
process in promoting the metastasis of cancer [14]. Erlotinib is a quinazolinamine derivative with 
the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine [15]. 
Erlotinib hydrochloride is very slightly soluble in water and methanol and is practically insoluble 
in acetone, acetonitrile, hexane and ethyl acetate. The solubility in water depends on pH which 
increases at a pH <5 as a result of the secondary amine's protonation. The solubility, nearly 0.4 
mg/ml, is observed to be best at a pH value of 2 with a pKa value of 5.42 at 25°C [16,17]. The 
chemical structure of Erlotinib is shown in Fig. 1. 
For this study, Chitosan was selected as a polymer due to its biocompatibility, biodegradability, 
safety and its bioadhesive nature. Chitos n is the principal component of exoskeletons of marine 
crustaceans from which supplements are often derived. Chitosan is a natural polycationic 
copolymer which consists of glucosamine units and N-acetyl glucosamine units. Chitosan is 
generally obtained by deacetylation of chitin derived from the exoskeleton of crustaceans [18]. 
The primary objective of the present work was to formulate the central composite designed 
erlotinib loaded chitosan nanoparticles using sonication technique. The main objective behind 
the work was to study the effect of three formulation variables i.e., the concentration of chitosan, 
the concentration of sodium tripolyphosphate (NaTPP) and sonication time on the particle size, 
drug entrapment and percent cumulative drug release of nanoparticles. Also, in the present study, 
authors used polyethylene glycol (PEG) as a surface stabilizer which helps to prevent the 
nanoparticles from opsonization and uptake by the reticuloendothelial system (RES) [19].  
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2. Materials and method 
2.1 Materials 
Erlotinib was obtained as a gift sample from Hetero Labs Limited, India. 95 percent deacetylated 
chitosan having a molecular weight around 40–80 kDa was procured from Fluka Chemika, 
Switzerland. Dimethyl Sulphoxide was purchased from Fisher Scientific Pvt. Ltd., India. Sodium 
tripolyphosphate (NaTPP), polyethylene glycol 600, glacial acetic acid, methanol and 
orthophosphoric acid were purchased from Loba Chemie Pvt. Ltd. India. The analytical grade 
was selected for all the other chemicals involved in the study, which were used as supplied by 
the manufacturer. 
2.2 Methods 
2.2.1 Preparation of erlotinib loaded chitosan nanoparticles 
In this study, the NPs were synthesized using sonication technique as reported by Kumar et al., 
2017 [20]. For this purpose, chitosan (0.1 – 0.3 percent w/v) was dissolved in glacial acetic acid 
(0.2 percent v/v). Double distilled water was used for the preparation of the solution of NaTPP 
(0.2 – 0.3 percent w/v). The drug solution was prepared separately by dissolving erlotinib (150 
mg) in methanol and dimethyl sulphoxide (1:1) and the surface stabilizers - PEG 600 (50 mg). 
During preliminary experimentation, the solubility studies of the drug was performed. It was 
observed that drug is highly soluble in methanol. The chitosan and drug solution were mixed 
together using magnetic stirrer at a speed of 1000 -1200 rpm for 4 h approximately. Then, 
NaTPP (100 ml) was added dropwise at a rate of 1 drop/s while magnetic stirring. Then, this 
solution was sonicated using probe sonicator at 40° C at different time interval i.e. 14 – 20 min; 
the obtained chitosan nanoparticle suspension was centrifuged at 26000 rpm for 30 min at 16° C. 
The supernatant was removed and chitosan nanoparticles were lyophilized using freeze-drying. 
The pictorial representation of the preparation of erlotinib loaded chitosan nanoparticles is shown 
in Fig. 2. 
2.2.2 Optimization of erlotinib loaded chitosan nanoparticles using central composite 
design 
Statistically designed experiments using central composite design (Design Expert® Software 
(Version 11.0.4.0, Stat-Ease Inc., Minneapolis, MN) were performed for determining the effect 
of three critical variables – concentration of chitosan (X1), concentration of NaTPP (X2) and 
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sonication time (X3) on the particle size, entrapment efficiency and percent cumulative drug 
release in 0.1N hydrochloric acid and Phosphate Buffer (PB) pH 6.8. The central composite 
design (CCD) constituting 6 (2n) batches on axial points (1S-6S), 8 (kn) batches of full factorial 
design (1F-8F) and 4 replicates at the centre points (1C-4C). The eighteen batches of erlotinib 
loaded chitosan nanoparticles (NP-1 to NP-18) are enlisted in Table 1. For nonlinear responses 
requiring second order models, CCDs are most frequently employed. The composite design 
contains an imbedded (2
k
) FD or (2
k-r
) FFD, augmented with group of star points (2k) and a 
central point. The total number of factor combinations in a CCD is 2
k
+2k+1. 
3. Characterization of erlotinib loaded chitosan nanoparticles  
3.1 Particle size, polydispersity index (PDI) and zeta potential 
For particle size and zeta potential analysis, the dilution of sample was analyzed by dissolving 
the sample (2 mg) in distilled water (5 ml) using Zetasizer nano series Nano-ZS90 (Malvern 
Instruments, Malvern, UK) which is equipped with the Hydro dispersing unit. Dilution of the 
sample was filled in a cuvette made up of polystyrene in hydro dispensing unit and then scan was 
carried out at a rate of 64 runs per sample. As the scan is completed, the average diameter per 
scan was taken out and recorded as Z-average for all the 64 runs [21-24].  
3.2 Loading capacity, entrapment efficiency and percentage yield  
The loading capacity, entrapment efficiency and percentage yield were determined directly using 
erlotinib loaded chitosan nanoparticles by analysis of the samples in suspension after 
centrifugation in sonication technique. The extracted erlotinib in the supernatant after 
ultracentrifugation of the nanoparticles suspension was determined using the high-performance 
liquid chromatography (HPLC) method. The HPLC analyses were carried out using a system 
(Agilent technologies 1200 series, Germany) that consisted reverse phase C18 column (25 cm × 
4.6 mm × 5 µm) with mobile phase consisting of 0.1 percent orthophosphoric acid and methanol 
(70:30 v/v) was used. The flow rate was 1.0 ml min
-1
 and the effluents were monitored at 247 
nm. Each sample was assayed in triplicate. The loading capacity, entrapment efficiency, and 
percentage yield were calculated according to the following equations [25]; 
                      Loading Capacity (percent)   =     
                     
                   
                                     (1) 
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                Entrapment Efficiency (percent)   =   
                    
          
                                      
(2) 
  Percentage Yield (percent)   =   
                         
                 
                                     
(3) 
3.3 In vitro release study 
In vitro drug release of erlotinib loaded chitosan nanoparticles was assessed by dialysis bag 
diffusion technique (specification: Av. Diameter-21.5 mm, Av. Flat width-32.34 mm, Capacity- 
3.63 ml/cm
2
) in 0.1N hydrochloric acid and PB pH 6.8. The prepared erlotinib loaded chitosan 
nanoparticles (weight equivalent to 150 mg of drug) were transferred to a cellulose dialysis bag 
(molecular weight cut-off 12000 Da; Himedia, Mumbai, India) which sealed from both ends. The 
dialysis bag was immersed in the cylindrical vessel of USP dissolution apparatus II (Lab India 
DS 8000, Mumbai, India) containing 200 ml of dissolution medium maintained at a temperature 
of 37°C±0.5°C. The rotating speed was set at 75 rpm. After certain time intervals in hours (0.5, 
1, 2, 4, 6, 8, 12, 18, 24), the aliquots of 2 ml were taken out from the release media at different 
time intervals and were replaced with the same volume of fresh receptor medium. The samples 
were analyzed by HPLC technique. All the experiments were performed in triplicate and the 
average values were assessed [26]. 
3.4 Drug release kinetic study 
The in vitro drug release data of the optimized erlotinib loaded chitosan nanoparticles were fitted 
to various kinectics equations such as zero order, first order, higuchi model and Korsmeyer-
peppas model. The correlation coefficient (R
2
) values were obtained for determining the 
mechanism and kinetics of drug release. In order to understand the mechanism and kinetics of 
drug release from tablets, the in vitro drug release study data was fitted into various kinetics 
equations [27].    
3.5 Differential scanning calorimetry (DSC) analysis 
DSC measurements were carried out on DSC Q10 V9.9, TA Instruments, Waters, USA. 
Calibration of the instrument was done by using indium as standard. Samples were placed in 
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sealed aluminium pans and heated from 30ºC to 300ºC at a rate of 10ºC/min under an 
atmosphere of nitrogen (60 ml/min), taking an empty pan as a reference [28].
 
3.6 Attenuated total reflectance (ATR) 
ATR spectrum was recorded on ATR Alpha, Bruker, Germany. The spectrum was recorded over 
the range of 500-3500 cm
-1
 [29].
 
3.7 X-ray diffraction (XRD) analysis 
The sample is installed on the instrument by holding it in place with one hand and with the other, 
press the stage up button until it locks. The slits in the ‘anti-scattering’ and ‘detector’ positions 
are verified as per the requirement of the procedure. The doors then slide together carefully and 
gently to interlock. After closing the doors, ‘XRD commander’ is expanded in the computer and 
power is raised if necessary. The scan is taken and auto-saved. When the task is finished sample 
is removed and enclosure doors are closed. The XRD s ectra of the pure drug erlotinib and 
optimized batch formulation were recorded at room temperature using x-ray diffractometer 
(XRD-D 8 Focus, Bruker, Germany) with a voltage of 40 kV, 40 mA current [30]. 
3.8 Transmission electron microscopy (TEM) 
The morphology and surface-appearance of nanoparticles were observed via FEI Company 
Tecnai TF20 high resolution Transmission Electron Microscope, Hillsboro, Oregon, USA. The 
TEM facility consists of a 200 KV TEM, equipped with a high brightness field-emission gun 
source which produces improved sensitivity and resolution compared to more traditional 
thermionic sources like LaB6 or Tungsten filaments. TEM is equipped with a 4K x 4K Eagle 
Charged Coupled Device camera with a 4-port readout. 5 µL sample was placed onto the carbon 
film-coated copper grid (300 mesh size) and allowed to settle down for 2 min. The excess of the 
sample was wiped out with tissue paper. The sample loaded grid was stained with 5 µL of 2 
percent uranyl acetate (negative stain) and allowed to settle down for 2 min. The excess stain 
was wiped out with tissue paper. Grid was allowed to dry for 3 h and visualized [31]. 
3.9 Cytotoxicity study 
3.9.1 Cell culture and treatment 
The A549 Lung cancer cells were procured and grown in DMEM media containing FBS (10 
percent), penicillin (100 units/ml) and streptomycin (100 µg/ml). The cells were maintained at 
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37°C in a 5 percent CO2 humidified incubator. After the cell became confluent, the culture media 
was removed and washed with 1 percent PBS solution to inactivate the existing media in culture. 
After that, treatment with trypsin-EDTA 0.25 percent (w/v) solution was given for trypsinization. 
Subsequently trypsin was inactivated by adding DMEM media, cells were collected and 
centrifuged at 1200 rpm at 37˚C for 5 min. The maintenance of cultured cell line was done in 25 
cm
2
 flask [32]. The same steps were repeated for maintaining the cells [33]. 
3.9.2 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
MTT assay was performed for evaluating the anti-proliferative potential of the compounds under 
investigation. 96-well plate method was used for carrying out this assay in which each well was 
filled with 100 µl complete media. Treatment was given as two concentrations viz., 1, and 5 µM 
and the cells were then incubated for 24 h. After 24 h, media was discarded with subsequent 
washing using 1X PBS and further treatment with MTT dye (5 mg in 10 mL of 1X PBS) and 
incubated again at room temperature thereafter in dark for 4 h to allow the formation of formazan 
crystals. The crystals were dissolved in dimethyl sulphoxide and resulting absorbance was 
spectrometrically read using microplate reader at 570 nm. The result was established in triplicate 
[32,33].
 
3.10 Stability studies 
For the development of a pharmaceutically satisfactory product, stability study is the most 
important evaluation parameter. Stability regarding any dosage form stands for its possible way 
to persist within the physical, chemical, toxicological and therapeutic specification. In the 
present study, the stability studies of optimized nanoparticle formulation were carried out after 
storing the formulation at freeze temperature (4°C±1°C), room temperature (25°C±2°C/ 60 
percent ±5 percent RH) and (45°C±2°C/ 75 percent ±5 percent RH) as per ICH guidelines. The 
optimized formulations were evaluated for various parameters such as particle size and percent 
cumulative drug release after 1, 2, 3 and 6 months. 
3.11 Comparison of in vitro diffusion profile with marketed formulation 
The optimized erlotinib loaded chitosan nanoparticles were compared with the marketed 
formulation of erlotinib (Erlocip-150, Cipla, India) for in vitro drug release. A model 
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independent approach was used employing a difference factor (f1) and similarity factor (f2) as 
given in Eq 4 and 5, respectively [34]. 
                                                          
        
   
                                 (4) 
                                              
 
   
 
  
        
                           (5) 
where, Rt = percent released for reference (marketed formulation) 
  Tt = percent released for test formulation (NP-7) at different time point 
 n = the number of time points in release profile. 
The time intervals used for determining the f1 and f2 values in this study were up to 24 h. The 
profiles of two drugs or formulations are considered similar if the values of f1 and f2 lies between 
0-15 and between 50-100, respectively. If the value comes less than 50, it indicates the release 
profiles of two drugs are different [35].  
4. Results and Discussion 
A total 18 formulations of erlotinib loaded chitosan nanoparticles were prepared using central 
composite design for optimizing three factors – concentration of chitosan (X1), the concentration 
of NaTPP (X2) and sonication time (X3) at two levels. All batches were analyzed to determine 
their particle size, polydispersity index, zeta potential, loading capacity, entrapment efficiency 
and percentage yield (Table 2). The results demonstrated that batch NP-7 prepared with a low 
concentration of chitosan, high concentration of NaTPP and high value of sonication time had 
shown highest loading capacity (77.15±0.15 percent) and entrapment efficiency (49.02±0.24 
percent) with particle size (138.5 nm) (Fig. 3a) having polydispersity index (PDI) value 0.382.  
The value of PDI > 0.7 reveals very wide particle size distribution i.e., the highly polydisperse 
system. The value of PDI < 0.5 reveals highly monodisperse system. The polydisperse system 
has a greater tendency to aggregate than the monodisperse system [36].  
The high loading capacity may be resulted due to the behaviour of a drug and chitosan in the 
solution. The cross-linking agent NaTPP also forms additional hydrogen bonds with the drug and 
chitosan leading to more compact nanoparticles which was confirmed by the ATR analysis. The 
hydrogen bonds between chitosan and drug were also concluded based on an earlier report [37]. 
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The affinity of TPP for the drug was increased by using surface stabilizer PEG 600 which 
consequently increased the drug loading. To assist the orthogonality of results and easy 
calculations, the real values of factors were transformed. The extent of contribution of different 
factors towards particle size, entrapment efficiency and in vitro drug release was determined by 
performing multiple linear regression analysis using Design Expert Software version 11.0.4.0. 
The effect of various parameters on different responses was determined using the polynomial 
equation, pareto plot, 3D response surface plot and contour plot constructed using Design 
Expert® software. A significant effect was determined to find percentage variability in different 
responses obtained and a probability value of P<0.05 was considered as significant level. 
Analysis of Variance was applied to all the response obtained to study the significance of the 
model. 
The polynomial equation for particle size is as follows:  
Particle Size = +446.15 + 88.02X1 – 34.55X2 + 157.61X3 + 62.75X1X2 + 52.03 X1X3 – 14.15 
X2X3 + 6.34 X1
2
 – 66.40 X2
2
 – 28.44 X3
2
 
The coefficient estimates the value of the concentration of chitosan (X1) and sonication time (X3) 
were found to be positive indicating that the increase in the concentration of chitosan and 
sonication time lead to an escalation in particle size whereas the concentration of NaTPP (X2) 
was found to be negative. The effects of various coefficients on particle size are shown in Fig. 
3(b). 
The quadratic model was found to be significant (p = 0.0289) with an F-value of 4.14 for particle 
size. The effect of main and interactive variables on the response was also determined. The p-
value of X1 was found to be 0.0314 and 0.3366, respectively, whereas the p-value for X3 was 
found to be 0.0016. In this case, X1 and X3 were significant model terms. 
The effect of different process variables on the response of particle size is also determined with 
the help of 3D response surface plot and contour plot as shown in Fig. 3(c) and 3(d), 
respectively. Analysis of Variance was applied to the responses obtained to assess the fitting and 
significance of model as shown in Table 3. 
The polynomial equation for entrapment efficiency is as follows:  
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Entrapment Efficiency = +71.84 – 3.20 X1 + 0.61 X2 + 2.06 X3 + 0.15 X1X2 - 0.41 X1X3 + 0.42 
X2X3 - 1.86 X1
2 – 0.53 X2
2 – 0.68 X3
2 
 
The coefficient estimates the value of concentration of chitosan (X1) was found to be negative 
indicated that entrapment efficiency increases with respect to the decrease in the corresponding 
variable whereas concentration of NaTPP (X2) and sonication time (X3) were found to be 
positive showed that entrapment efficiency increases with respect to the increase in the 
corresponding variables. The effects of various coefficients for entrapment efficiency are shown 
in Fig. 4(a). 
The quadratic model was found to be significant (p = 0.0022) with an F-value of 9.41 for 
entrapment efficiency. The p-value of X1 and X2 were found to be 0.0002 and 0.2208, 
respectively, whereas the p-value for X3 was found to be 0.0022. In this case, X1, X3 and X1
2
 
were significant model terms. 
The effect of different process variables on the response of entrapment efficiency is determined 
with the help of 3D response surface plot and contour plot as shown in Fig. 4(b) and 4(c), 
respectively. Analysis of Variance was applied to the response obtained for studying the fitting 
and significance of the model (Table 3). 
The polynomial equation for percent cumulative drug release in 0.1N hydrochloric acid is as 
follows:  
Percent Cumulative Drug Release = +76.95 – 1.22X1 + 1.01X2 + 0.68X3 – 0.52X1X2 + 0.29 X1X3 
+ 0.34 X2X3 + 1.73 X1
2 
+ 2.25 X2
2 
+ 4.17 X3
2 
The coefficient estimates value of concentration of chitosan (X1) was found to be negative, 
which indicates that percent cumulative drug release increases with respect to the decrease in the 
corresponding variable whereas concentration of NaTPP (X2), sonication time (X3) which 
indicates that percent cumulative drug release increases with respect to the increase in the 
corresponding variable. The effects of various coefficients on percent cumulative drug release 
are shown in Fig. 5(a).  
The quadratic model was found to be significant (p = 0.0408) with an F-value of 3.65 for percent 
cumulative drug release in 0.1N hydrochloric acid. The p-value of X1 and X2 were found to be 
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0.0169 and 0.2492, respectively, whereas the p-value for X3 was found to be 0.4202. In this case, 
X1, X2
2
 and X3
2
 were significant model terms. 
The effect of different process variables on the response of percent cumulative drug release is 
determined with the help of 3D response surface plot and contour plot as shown in Fig. 5(b) and 
5(c), respectively. Analysis of Variance was applied on the response obtained for evaluating the 
fitting and significance of model (Table 3). 
The polynomial equation for percent cumulative drug release in PB pH 6.8 is as follows:  
percent Cumulative Drug Release = +23.35 – 0.91X1 + 1.05X2 + 0.76X3 – 0.43X1X2 + 0.79 X1X3 
- 0.10 X2X3 + 3.29 X1
2 
+ 2.59 X2
2 
+ 5.38 X3
2
 
The coefficient estimates value of concentration of chitosan (X1) was found to be negative which 
indicates that percent cumulative drug release increases with respect to the decrease in the 
corresponding variable whereas concentration of NaTPP (X2), sonication time (X3) were found 
to be positive which indicates that percent cumulative drug release increases with respect to the 
increase in the corresponding variable. The effects of various coefficients on percent cumulative 
drug release in shown in Fig. 6(a). 
The quadratic model was found to be significant (p = 0.0264) with an F-value of 4.27 for percent 
cumulative drug release in PB pH 6.8. The p-value of X1 and X2 were found to be 0.3696 and 
0.3084, respectively, whereas the p-value for X3 was found to be 0.4471. In this case, X1
2
, X2
2
 
and X3
2
 were significant model terms. 
The effect of different process variables on the response of percent cumulative drug release is 
also determined with the help of 3D response surface plot and contour plot as shown in Fig. 6(b) 
and 6(c), respectively. Analysis of Variance was applied to the response obtained to study the 
fitting and significance of the model (Table 3). 
4.1 In vitro release studies 
In vitro drug release of central composite designed erlotinib loaded chitosan nanoparticles using 
sonication technique was evaluated using 0.1N hydrochloric acid and PB pH 6.8 by dialysis bag 
diffusion technique [20]. The in vitro release study of erlotinib was investigated in two different 
media i.e. 0.1N hydrochloric acid and PB pH 6.8 to analyze the amount of drug released in acidic 
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environment as well as in simulated intestinal fluid. The cumulative drug release of all the 
batches in 0.1N hydrochloric acid ranged from 76.81 percent to 91.57 percent after 24 h. Out of 
all the formulations, NP-7 containing the low value of chitosan, the high value of NaTPP and 
high value of sonication time had shown maximum release i.e. 91.57 percent of erlotinib loaded 
chitosan nanoparticles in 0.1N hydrochloric acid after 24 h. Cumulative drug release for all the 
central composite designed erlotinib loaded chitosan nanoparticles in PB pH 6.8 ranged from 
23.10 percent to 39.78 percent after 24 h. The higher percent CDR was found in an acidic buffer 
in comparison to basic buffer as erlotinib is a free base and is more susceptible to dissolve in the 
acidic solution. Out of all the formulations, NP-7 had shown maximum release i.e. 39.78 percent 
of erlotinib loaded chitosan nanoparticles in PB pH 6.8 after 24 h. The release rate of erlotinib 
from chitosan nanoparticles exhibited a sustained release profile in the 0.1N hydrochloric acid 
and PB pH 6.8 and the release rate of erlotinib was highest in the simulated gastric fluid medium 
after 24 h. The sustained release manner of the central composite designed erlotinib loaded 
chitosan nanoparticles may extend the time of absorption of the drug in the gastrointestinal tract, 
which might be helpful to enhance the therapeutic activity of the drug and to reduce the side 
effects. The reason for carrying out the in vitro release study of Erlotinib in two different media 
i.e. 0.1 N hydrochloric acid and PB pH 6.8 was to confirm the release of Erlotinib in both the 
basic as well as in the acidic environment. Although the drug solubilizes in both the media, it 
dissolves faster in acidic medium. 
4.2 Release kinetics 
Among all the models applied in the study, Higuchi model showed the highest value of R
2
 for in-
vitro release data for NP-7 obtained in the 0.1N hydrochloric acid (0.999) and PB pH 6.8 
(0.991). In this study, the value of n in Korsmeyer-Peppas model for in vitro release data in 0.1N 
hydrochloric acid and PB pH 6.8 was found to be 0.689 and 0.929, respectively which suggested 
that the mechanism for release followed by the erlotinib loaded chitosan nanoparticles using 
sonication technique is non-fickian anomalous diffusion, suggesting that the drug release is 
controlled by all the mechanisms including erosion, diffusion and swelling. But the highest R
2
 
value for the Higuchi model showed the release mechanism followed primarily is diffusion in 
comparison to erosion and swelling. The results recommended that the erlotinib hydrochloride 
release from the formulated nanoparticles occurred mainly by the diffusion mechanism i.e. the 
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dissolution medium permeates into the polymeric matrix of erlotinib nanoparticles, slowly 
dissolves the erlotinib and drug is released to the dissolution medium by diffusion mechanism. 
4.3 Differential scanning calorimetry 
The disappearance of endothermic peak of the optimized batch NP-7 including all the batches of 
central composite designed erlotinib loaded chitosan nanoparticles using sonication technique 
showed that drug may have been dispersed or dissolved in the polymer matrix during the 
formation of nanoparticles.  The total incorporation of the drug into the nanoparticles suggested a 
molecular dispersion of drug inside the system. The nano-entrapment process produced a marked 
decrease in crystallinity of erlotinib and allows a nearly amorphous state [25]. The DSC 
thermogram of erlotinib, chitosan and optimized batch NP-7 are sh wn as an overlay in Fig. 7(a). 
The overlay of DSC thermograms of central composite designed erlotinib loaded chitosan 
nanoparticles of NP-1 to NP-6, NP-7 to NP-12 and NP-13 to NP-18 are shown in Fig. 7(b)-7(d), 
respectively.  
4.4 Attenuated total reflectance 
The ATR spectrum of erlotinib hydrochloride, chitosan and the optimized batch NP-7 are shown 
as overlay in Fig. 8(a). There was no significant difference in the ATR spectra of erlotinib 
hydrochloride and all the batches of central composite designed erlotinib loaded chitosan 
nanoparticles using sonication technique. On comparing the obtained spectra with the reference 
spectra, no overlapping of characteristic peaks, no significant shifting of functional peaks, and 
also no new peaks were observed in case of optimized batch NP-7. The results suggested that the 
drug was stable during the process of entrapment. The ATR data also suggested that there was no 
molecular interaction and no chemical interaction between functional groups of the polymer and 
drug occurred during the process [38]. The overlay of ATR of central composite designed 
erlotinib loaded chitosan nanoparticles of NP-1 to NP-6, NP-7 to NP-12 and NP-13 to NP-18 are 
shown in Fig. 8(b)-8(d), respectively. 
4.5 XRD analysis 
Powder X-ray diffraction pattern of pure drug erlotinib hydrochloride and chitosan are shown in 
Fig. 9(a) and 9(b), respectively. The 2θ value of erlotinib at 38.04°, 27.86°, 27.84°, 27.78°, 
26.64°, 25.92°, 24.88°, 22.94°, 20.74°, 18.26°, 17.32° and 15.12° strongly indicated crystalline 
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nature of erlotinib hydrochloride. The x-ray diffraction of optimized batch NP-7 displayed the 
existence of erlotinib hydrochloride in amorphous pattern as shown in Fig. 9(c).  
4.6 Transmission electron microscopy 
The TEM image of the optimized batch of central composite designed erlotinib loaded chitosan 
nanoparticle NP-7 is shown in Fig. 10. The optimized batch NP-7 was found to be spherical in 
shape. TEM was used at the nanoscale with magnification 25k. 
4.7 Stability studies 
The optimized batch NP-7 was subjected to stability studies. The formulation NP-7 was found 
stable after six-month study as no considerable transformation was detected in the above 
parameters as shown in Table 4. The size of the NP-7 increased with the rise in time intervals 
due to the aggregation of the particles. The increase in particle size of NP-7 formulation was 
found to be least at 4°C as compared with the formulation stored at room temperature and 45°C 
for six-months. The percent cumulative drug release (0.1N hydrochloric acid and PB pH 6.8) 
decreased after storage. At 45°C, the maximum fall in percent cumulative drug release of 
optimized batch NP-7 was seen as compared with the formulation stored at room temperature 
and 4°C for six months. From the results, it can be concluded that for better stability, the 
formulation should be stored at 4°C. 
4.8 Comparison with marketed formulation 
The optimized batch NP-7 showed 10.86 percent and 2.56 percent of drug release in 0.1N 
hydrochloric acid and PB pH 6.8 within 1 h, respectively whereas the marketed tablet released 
81.46±0.23 percent and 26.78±0.12 percent in 0.1N hydrochloric acid and PB pH 6.8 within 1 h, 
respectively. After 24 h, the optimized batch showed 91.57 percent and 39.78 percent of drug 
release in 0.1N hydrochloric acid and PB pH 6.8, respectively, whereas the marketed tablet 
released 95.76 percent and 44.54 percent in 0.1N hydrochloric acid and PB pH 6.8 within 24 h, 
respectively (Table 5). The optimized nanoparticle formulation NP-7 released erlotinib slowly in 
comparison to marketed tablet formulation which may help in improving the therapeutic efficacy 
of the drug and reducing the side effects of conventional tablet dosage form [39]. 
4.9 Comparison of in vitro diffusion profiles 
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In the present study, in vitro release was found to be slow for optimized nanoparticle 
formulations (NP-7) in comparison to the available tablet formulation in the market. The 
cumulative amount of drug release for NP-7 at 24 h was found to be 39.78±0.78 percent and for 
Erlocip tablets, it was observed to be 44.54±0.42. The slow drug release from the optimized 
formulations may be attributed to the property of nanoformulation of making the drug slowly 
available for release and hence the synthesized nanoparticles of erlotinib hydrochloride showed 
slow in vitro drug release than the available marketed formulation. The f1 and f2 values for the 
NP-7 as compared to that of the marketed Erlocip-150 tablets, when calculated using the 
equation at 24 hrs were found to be 51.06 and 14.28, respectively. 
4.10 Cytotoxic studies 
Cytotoxic activity of the pure drug erlotinib hydrochloride and central composite designed 
erlotinib loaded chitosan nanoparticles using sonication technique (NP-7 and NP-13) were 
studied.  The reason for selecting two batches for cytotoxicity studies were to compare the batch 
having the minimum particle size (NP-13) and other batch (NP-7) having the maximum loading 
capacity and entrapment efficiency. The batch NP-7 and NP-13 showed the maximum inhibition 
of lung cancer (A549) cells. Among both the batches, NP-13 had shown more cytotoxicity in 
comparison to NP-7 because the NP-13 had less particle size and more zeta potential value. It 
has been reported that the drug uptake in cancer cells is highly dependent on the particle size and 
higher value of positive zeta potential facilitate cytotoxicity in cancer cells due to stronger 
interaction with the tumor cell membrane. Free erlotinib hydrochloride had shown more 
cytotoxicity than the erlotinib loaded chitosan nanoparticles (NP-7 and NP-13). The less 
cytotoxicity of erlotinib loaded chitosan nanoparticles might be due to the slow release rate of 
erlotinib loaded chitosan nanoparticles (NP-7 and NP-13) [40]. The IC50 value of free erlotinib 
was 1.03 µM while the IC50 value of NP-7 and NP-13 were 6.36 µM and 5.95 µM, respectively. 
In this study, the cytotoxicity of the central composite designed erlotinib loaded chitosan 
nanoparticles might be associated with the particle size and zeta potential.  The IC50 values of the 
pure drug erlotinib hydrochloride and the nanoparticle formulation (NP-7 and NP-13) are shown 
in Table 6. 
5. Conclusion 
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The formulation of nanoparticles by ionic-gelation method utilizing sonication technique was 
found to be an effective and simple method in which the particle size and distribution of the drug 
can be monitored by varying the variables like the concentration of chitosan, the concentration of 
NaTPP and sonication time. Erlotinib loaded chitosan nanoparticles were successfully prepared 
by applying CCD with effective use of surface stabilizing agent PEG 600. The optimized 
nanoparticles were obtained with a particle size range which can be effective in prolonging the 
circulation time of the drug helping in the delivery of the drug at the target site. The 
mathematical developed models can be used further for the formulation of nanoparticles with the 
desired characteristics. The f1 value higher than 15 and f2 lower than 50 indicated differences in 
the in vitro release profiles of the prepared and optimized nano-formulations and the marketed 
Erlotinib hydrochloride tablet (Erlocip-150). The formulated nanoparticles showed non-fickian 
mechanism for diffusion indicating that the release of drug is controlled by all diffusion, erosion 
and swelling mechanisms. The nanoparticle showed the maximum cytotoxic effect on A549 
cancer cell line. The stability studies concluded that the nanoparticle formulations should be 
stored at 4°C. The optimized nanoparticle formulation released erlotinib slowly in comparison to 
marketed tablet formulation which may help in improving the therapeutic efficacy of the drug 
and reducing the side effects of the existing conventional tablet dosage form. 
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Table 1  
Formulation 
Code  
Concentration of Chitosan 
(percent w/v) (X1) 
Concentration of NaTPP 
(percent w/v) (X2) 
Sonication Time 
(min) (X3) 
NP-1 -1 (0.1) -1 (0.2) -1 (14) 
NP-2 +1 (0.2) -1 (0.2) -1 (14) 
NP-3 -1 (0.1) +1 (0.3) -1 (14) 
NP-4 +1 (0.2) +1 (0.3) -1 (14) 
NP-5 -1 (0.1) -1 (0.2) +1 (20) 
NP-6 +1 (0.2) -1 (0.2) +1 (20) 
NP-7 -1 (0.1) +1 (0.3) +1 (20) 
NP-8 +1 (0.2) +1 (0.3) +1 (20) 
NP-9 -1.682 (0.0659) 0 (0.25) 0 (17) 
NP-10 +1.682 (0.234) 0 (0.25) 0 (17) 
NP-11 0 (0.15) -1.682 (0.166) 0 (17) 
NP-12 0 (0.15) +1.682 (0.334) 0 (17) 
NP-13 0 (0.15) 0 (0.25) -1.682 (11.95) 
NP-14 0 (0.15) 0 (0.25) +1.682 (22.04) 
NP-15 0 (0.15) 0 (0.25) 0 (17) 
NP-16 0 (0.15) 0 (0.25) 0 (17) 
NP-17 0 (0.15) 0 (0.25) 0 (17) 
NP-18 0 (0.15) 0 (0.25) 0 (17) 
*The values in bracket indicate real values 
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Table 2 
Formulation 
Code 
Particle Size 
(nm) 
PDI Zeta 
Potential 
Percentage 
Yield 
(percent) 
Loading 
Capacity 
(percent) 
Entrapment 
Efficiency 
(percent) 
NP-1 250.8 0.783 26.9 68.07 69.23±0.45 41.54±0.54 
NP-2 242.7 0.534 24.1 66.60 61.22±0.15 44.33±0.42 
NP-3 134.7 0.469 28.4 74.77 69.55±0.48 42.69±0.77 
NP-4 139.7 0.392 31.7 71.89 63.46±0.34 34.02±0.26 
NP-5 549.1 0.922 24.7 64.43 73.84±0.41 47.62±0.17 
NP-6 511.2 0.385 21.9 62.10 65.46±0.85 38.14±0.34 
NP-7 138.5 0.382  26.3 67.44 77.15±0.15 49.02±0.24 
NP-8 589.5 0.720 22.2 63.00 68.12±0.38 39.20±0.35 
NP-9 282.5 0.462 23.8 65.22 70.95±0.23 33.62±0.25 
NP-10 753.5 0.778 15.9 66.34 63.35±0.41 37.58±0.47 
NP-11 288.6 0.798 16.2 59.94 70.74±0.20 43.33±0.49 
NP-12 335.9 0.353 24.5 64.10 70.69±0.14 44.28±0.56 
NP-13 83.06 0.295 13.5 67.25 68.19±0.32 41.22±0.44 
NP-14 756.2 0.516 18.1 58.86 72.39±0.24 46.43±0.62 
NP-15 419.8 0.481 26.2 66.80 71.88±0.29 45.50±0.31 
NP-16 450.7 0.405 25.9 66.95 71.21±0.16 45.36±0.13 
NP-17 460.8 0.658 25.8 66.21 71.97±0.61 45.58±0.19 
NP-18 434.8 0.412 25.4 67.10 72.18±0.45 45.11±0.32 
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Table 3  
S. No. Response Source of 
Variation 
Degree of 
Freedom 
Sum of 
Squares 
Mean Square F-Value P-Value  
1. Particle Size Model 9 581765.27 64640.58 4.14 0.0289* Significant 
Residual 8 124818.98 15602.37 - 
Total 17 706584.26 - - 
2.  Entrapment 
Efficiency 
Model 9 250.87 27.87 9.41 0.0022* Significant 
Residual 8 23.69 2.96 - 
Total 17 274.56 - - 
3. Percent 
Cumulative Drug 
Release in 0.1N 
hydrochloric acid 
Model 9 294.85 32.76 3.65 0.0408* Significant 
Residual 8 71.71 8.96 - 
Total 17 366.56 - - 
4. Percent 
Cumulative Drug 
Release in PB pH 
6.8 
Model 9 485.55 53.95 4.27 0.0264* Significant 
Residual 8 101.01 12.63 - 
Total 17 586.55 - - 
*P<0.05
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Table 4 
Evaluation 
Parameter 
Temperature Time Intervals in Months 
1 2 3 6  
Particle Size (nm) 4°C 144.6 151.2 159.5 167.9 
Room 
Temperature 
146.6 153.5 162.0 173.2 
45°C 152.1 158.1 166.4 177.4 
Percent Cumulative 
Drug Release in 0.1N 
Hydrochloric Acid 
4°C 90.22±0.12 89.68±0.23 88.70±0.11 87.78±0.22 
Room 
Temperature 
89.76±0.15 88.97±0.14 88.02±0.17 87.12±0.24 
45°C 88.58±0.08 87.72±0.19 87.23±0.07 86.76±0.29 
Percent Cumulative 
Drug Release in PB 
pH 6.8 
4°C 39.47±0.10 39.30±0.05 39.12±0.11 38.90±0.13 
Room 
Temperature 
39.34±0.21 39.10±0.12 38.96±0.20 38.65±0.17 
45°C 39.24±0.18 38.92±0.19 38.80±0.14 38.33±0.08 
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Table 5 
Time 
Interval 
Percent Cumulative Amount of Drug 
Released from Optimized Batch in 
Different Media 
Percent Cumulative Amount of 
Drug Released from Pure Drug in 
Different Media 
Percent Cumulative Amount of Drug 
Released from Marketed Tablet in 
Different Media 
0.1 N Hydrochloric 
Acid 
PB pH 6.8 0.1 N Hydrochloric 
Acid 
PB pH 6.8 0.1 N Hydrochloric 
Acid 
PB pH 6.8 
0.5 6.12±0.26 1.12±0.12 64.22±0.06 19.45±0.21 80.12±0.34 25.56±0.46 
1 10.86±1.02 2.56±0.34 65.09±0,18 21.69±0.14 81.46±0.23 26.78±0.12 
2 17.43±1.31 4.89±0.43 66.89±0.24 24.65±0.18 83.54±0.18 28.92±0.24 
4 31.45±1.24 9.22±0.15 69.32±0.09 27.94±0.10 84.88±-0.46 31.65±0.32 
6 37.67±1.87 14.58±0.18 72.23±0.11 29.89±0.22 87.92±0.32 33.56±0.42 
8 45.20±1.65 20.78±0.26 75.55±0.25 31.56±0.11 88.23±0.45 36.78±0.15 
12 58.17±1.62 26.16±0.54 78.76±0.31 35.03±0.17 90.89±0.56 39.84±0.45 
18 76.88±1.41 32.88±0.27 80.92±0.28 38.66±0.09 93.46±0.46 42.90±0.38 
24 91.57±1.32 39.78±0.78 83.77±0.15 42.12±0.16 95.76±0.28 44.54±0.42 
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Table 6 
S. No. Treatment Ic50 Value (Μm) 
1. Pure Drug 1.03±0.02 
2. NP-13 5.95±0.08 
3. NP-7 6.36±0.09 
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Fig. 1. Structure of Erlotinib. 
Fig. 2. Pictorial representation of preparation of erlotinib loaded chitosan nanoparticles. 
Fig. 3. (a) Particle Size Analysis and Polydispersity Index of NP – 7 (b) Pareto Chart for 
Coefficients of Particle Size (b1, b2, b3 = coefficients of main terms; b4, b5, b6 = coefficients of 
interaction terms and b7, b8, b9 = coefficients of square terms). (c) 3D Response Surface Plot 
indicating the effect of different process variables on Particle Size. (d) Contour Plot indicating 
the effect of different process variables on Particle Size. 
Fig. 4. (a) Pareto Chart for Coefficients of Entrapment Efficiency (b1, b2, b3 = coefficients of 
main terms; b4, b5, b6 = coefficients of interaction terms and b7, b8, b9 = coefficients of square 
terms). (b) 3D Response Surface Plot indicating the effect of different process variables on 
Entrapment Efficiency. (c) Contour Plot indicating the effect of different process variables on 
Entrapment Efficiency. 
Fig. 5. (a) Pareto Chart for Coefficients of percent Cumulative Drug Release in 0.1N 
Hydrochloric Acid (b1, b2, b3 = coefficients of main terms; b4, b5, b6 = coefficients of 
interaction terms and b7, b8, b9 = coefficients of square terms). (b) 3D Response Surface 
indicating the effect of different process variables on percent Cumulative Drug Release in 0.1N 
Hydrochloric Acid. (c) Contour Plot indicating the effect of different process variables on 
percent Cumulative Drug Release in 0.1N Hydrochloric Acid. 
Fig. 6. (a) Pareto Chart for Coefficients of percent Cumulative Drug Release in PB pH 6.8 (b1, 
b2, b3 = coefficients of main terms; b4, b5, b6 = coefficients of interaction terms and b7, b8, b9 
= coefficients of square terms). (b) 3D Response Surface indicating the effect of different 
process variables on percent Cumulative Drug Release in PB pH 6.8. (c) Contour Plot indicating 
the effect of different process variables on percent Cumulative Drug Release in PB pH 6.8. 
Fig. 7. (a) An Overlay of DSC Thermograms of Erlotinib, Chitosan and the Optimized Batch 
NP-7. (b) An Overlay of DSC Thermograms of Central Composite Designed Erlotinib Loaded 
Chitosan Nanoparticles of NP-1 to NP-6. (c) An Overlay of DSC Thermograms of Central 
Composite Designed Erlotinib Loaded Chitosan Nanoparticles of NP-7 to NP-12. (d) An 
Overlay of DSC Thermograms of Central Composite Designed Erlotinib Loaded Chitosan 
Nanoparticles of NP-13 to NP-18. 
Fig. 8. (a) ATR Spectrum of Erlotinib Hydrochloride, Chitosan and the Optimized Batch NP-7. 
(b) An Overlay of ATR of Central Composite Designed Erlotinib Loaded Chitosan 
Nanoparticles of NP-1 to NP-6. (c) An Overlay of ATR of Central Composite Designed Erlotinib 
Loaded Chitosan Nanoparticles of NP-7 to NP-12. An Overlay of ATR of Central Composite 
Designed Erlotinib Loaded Chitosan Nanoparticles of NP-13 to NP-18. 
Fig. 9. (a) XRD of the Pure Drug – Erlotinib Hydrochloride (b) XRD of the Polymer – Chitosan 
(c) XRD of Optimized Batch NP-7. 
Fig. 10. TEM of Optimized Batch NP-7. 
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Chitosan (0.1 – 0.3 percent w/v) dissolved in glacial acetic acid (0.2 percent v/v). 
 
Solution of NaTPP (0.2 – 0.3 percent w/v) using double distilled water. 
 
Solution of erlotinib (150 mg) in methanol and dimethyl sulphoxide (1:1) along with the 
surface stabilizers - PEG 600 (50 mg). 
  
 
Addition of NaTPP solution at the rate of 1 drop/s  
 
Sonication of resulting solution using probe sonicator for 14 – 20 min 
 
Centrifugation of nanoparticle suspension at 26000 rpm for 30 min 
 
Lyophilization of prepared chitosan nanoparticles 
Fig. 2. 
 
Mixing of chitosan and erlotinib solution at the speed of 1000 -1200 rpm for ~ 4 h  
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Fig. 3. 
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Fig. 4. 
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Fig. 5. 
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Fig. 7a 
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Fig. 7b 
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Fig. 7c 
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Fig. 7d 
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Fig. 8a 
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Fig. 8b 
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Fig. 8c 
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Fig. 8d 
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Fig. 9. 
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Fig.  10. 
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